ConductScience.org, home

Paper17517853

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE and 1 other. N Engl J Med, 2007. Cited by 3,569 papers, by iCite.

Cite this record

ConductScience Library. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Papers, record 17517853. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17517853

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
PubMed
Journal
N Engl J Med
PubMed
Year
2007
PubMed
Publication types
Journal Article, Meta-Analysis
PubMed
Citations, by iCite
3,569
iCite
Relative citation ratio, by iCite
92.4
iCite
Revised in PubMed
2026-01-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nissen SESteven E
2Wolski KKathy

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Hypoglycemic AgentsMajor topic
Myocardial InfarctionMajor topic
ThiazolidinedionesMajor topic
Glycated Hemoglobin
Humans
Middle Aged
Odds Ratio
Randomized Controlled Trials as Topic
Risk Assessment
Rosiglitazone

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00868933Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver DiseaseBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections14

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in17517854Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17517854PubMed
Comment in17551160Rosiglitazone--continued uncertainty about safety.https://conductscience.org/library/papers/17551160PubMed
Comment in17551161Rosiglitazone and cardiotoxicity--weighing the evidence.https://conductscience.org/library/papers/17551161PubMed
Comment in17551162The record on rosiglitazone and the risk of myocardial infarction.https://conductscience.org/library/papers/17551162PubMed
Comment in17761600Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17761600PubMed
Comment in17806134Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17806134PubMed
Comment in17806135Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17806135PubMed
Comment in17806136Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17806136PubMed
Comment in17848926Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?https://conductscience.org/library/papers/17848926PubMed
Comment in17925798Is rosiglitazone associated with increased risk for cardiovascular events?https://conductscience.org/library/papers/17925798PubMed
Comment in17975868Review: rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes.https://conductscience.org/library/papers/17975868PubMed
Comment in18022724Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH).https://conductscience.org/library/papers/18022724PubMed
Comment in18063729Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes.https://conductscience.org/library/papers/18063729PubMed
Comment in20647188Don't mess with the DSMB.https://conductscience.org/library/papers/20647188PubMed

Download CSV of comments and corrections

Cited by1,539

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,569 citations.

PMIDTitleJournalYearIn PapersSource
42839993Reduced serum adiponectin and exercise predict depression in chronic heart failure patients and affect depressive-like behaviors in a mouse model.Front Physiol2026https://conductscience.org/library/papers/42839993PubMed
42774918Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease.Kidney Int Rep2026https://conductscience.org/library/papers/42774918PubMed
42755691Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization.Hypertension2026https://conductscience.org/library/papers/42755691PubMed
42719321Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH).Drug Des Devel Ther2026https://conductscience.org/library/papers/42719321PubMed
42695164The Portability of Surrogate Endpoints.J Clin Pharmacol2026https://conductscience.org/library/papers/42695164PubMed
42667518Antidiabetic medications and arterial thrombotic risk reduction: a narrative review.Intern Emerg Med2026https://conductscience.org/library/papers/42667518PubMed
42614881The Substrate-Engine Model of Ferroptosis: Stage-Specific Targeting of Acyl-CoA Synthetase Long-Chain Family Member 4 and 5‑Lipoxygenase in Alzheimer's Disease.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/42614881PubMed
42584735Peroxisome proliferator-activated receptor gamma (PPARγ) as a mechano-metabolic transducer: coordinating lipid homeostasis through mechanical cues.Mol Biomed2026https://conductscience.org/library/papers/42584735PubMed
42568490Incretin analogues as cardiovascular agents: a state-of-the-art review.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42568490PubMed
42466348Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42466348PubMed
42440427Effectiveness of low-dose SGLT2 inhibitors in diabetic patients with heart failure: a nationwide cohort study.Front Cardiovasc Med2026https://conductscience.org/library/papers/42440427PubMed
42354854The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review.Microorganisms2026https://conductscience.org/library/papers/42354854PubMed
42351310From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.Cardiovasc Diabetol Endocrinol Rep2026https://conductscience.org/library/papers/42351310PubMed
42316327Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42316327PubMed
42292795Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study.Front Pharmacol2026https://conductscience.org/library/papers/42292795PubMed
42283795Analytic Misjudgment of Drug Safety Evidence and Causality: From the Prosecutor's Fallacy and Simpson's Paradox to Artificial Intelligence.Drug Saf2026https://conductscience.org/library/papers/42283795PubMed
42157659Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea.J Diabetes Investig2026https://conductscience.org/library/papers/42157659PubMed
42060802After the green light: Evaluating drugs in Phase IV studies.Indian J Pharmacol2026https://conductscience.org/library/papers/42060802PubMed
42016855Neuron-targeted 2-deoxyglucose-dendrimer-rosiglitazone nanotherapy mitigates neuroinflammation and cognitive deficits in pediatric traumatic brain injury.Bioeng Transl Med2026https://conductscience.org/library/papers/42016855PubMed
42006047Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden.Toxicol Rep2026https://conductscience.org/library/papers/42006047PubMed

See all 1,539 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17517853

GET https://conductscience.org/api/papers/v1/17517853/cited_by?page=2